GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BioSig Technologies Inc (NAS:BSGM) » Definitions » Cash-to-Debt

BioSig Technologies (BioSig Technologies) Cash-to-Debt : 0.65 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is BioSig Technologies Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. BioSig Technologies's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.65.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, BioSig Technologies couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for BioSig Technologies's Cash-to-Debt or its related term are showing as below:

BSGM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.6   Med: 5045.01   Max: No Debt
Current: 0.65

During the past 11 years, BioSig Technologies's highest Cash to Debt Ratio was No Debt. The lowest was 0.60. And the median was 5045.01.

BSGM's Cash-to-Debt is ranked worse than
69.33% of 864 companies
in the Medical Devices & Instruments industry
Industry Median: 1.845 vs BSGM: 0.65

BioSig Technologies Cash-to-Debt Historical Data

The historical data trend for BioSig Technologies's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

BioSig Technologies Cash-to-Debt Chart

BioSig Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.75 90.03 17.77 0.60 0.65

BioSig Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.60 2.20 2.21 0.92 0.65

Competitive Comparison of BioSig Technologies's Cash-to-Debt

For the Medical Devices subindustry, BioSig Technologies's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioSig Technologies's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BioSig Technologies's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where BioSig Technologies's Cash-to-Debt falls into.



BioSig Technologies Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

BioSig Technologies's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

BioSig Technologies's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioSig Technologies  (NAS:BSGM) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


BioSig Technologies Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of BioSig Technologies's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


BioSig Technologies (BioSig Technologies) Business Description

Traded in Other Exchanges
N/A
Address
55 Greens Farms Road, 1st Floor, Westport, CT, USA, 06880
BioSig Technologies Inc is a commercial stage medical device company. It is developing a proprietary technology platform to minimize noise and artifacts from cardiac recordings during electrophysiology studies and ablation.
Executives
Kenneth L Londoner director, 10 percent owner 10 RED COAT ROAD, WESTPORT CT 06880
Steven J Buhaly officer: Chief Financial Officer 1195 NW LOMPTON DRIVE, BEAVESTON OR 97006
John Sieckhaus officer: Chief Operating Officer C/O BIOSIG TECHNOLOGIES, 55 GREENS FARMS ROAD, WESTPORT CT 06880
Steve Chaussy officer: Chief Financial Officer 9780 E AVE, HESPERIA CA 92345
Patrick Joseph Gallagher director 275 PLEASANT HILL RD., FLANDERS NJ 07836
Gray Fleming officer: Chief Commercial Officer C/O BIOSIG TECHNOLOGIES, INC., 55 GREENS FARMS ROAD, WESTPORT CT 06880
James L Klein director 2300NE BROOKWOOD PKWY, HILLSBORO OR 97124
Frederick Hrkac director C/O BIOSIG TECHNOLOGIES, 55 GREENS FARMS ROAD, WESTPORT CT 06880
James J Barry director C/O INSPIREMD, INC., 4 MENORAT HAMAOR ST., TEL AVIV L3 6744832
Jeffrey F Odonnell director 126 ROSSMORE DRIVE, MALVERN PA 19355
Anthony P. Zook director C/O VIVUS, INC., 351 EAST EVELYN AVENUE, MOUNTAIN VIEW CA 94041
Jerome B Zeldis director 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Martha Pease director 33 SEAVIEW, MADISON CT 06443
John M Kowalski officer: VP of Sales 54 WILTON ROAD, 2ND FLOOR, WESTPORT CT 06880
Samuel E Navarro director C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044